- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Optimizing Oncology Workflows: The Shift From IV to Subcutaneous Treatments
A panel of experts describes the impact of subcutaneous formulations on oncology workflows and discusses actionable strategies for oncology practice transformation to successfully integrate subcutaneous therapies into clinical workflows.
EP. 1: The Shifting to Subcutaneous Oncology: Recent FDA Approvals
Panelists discuss how the shift from intravenous (IV) to subcutaneous (SubQ) drug administration is transforming oncology care delivery, highlighting its lasting impact on patient experience, health care efficiency, and clinical workflows in light of recent FDA approvals and evolving pharmaceutical strategies.
Watch
EP. 2: Subcutaneous Value: Efficiency and Access
Panelists discuss how subcutaneous (SubQ) drug formulations offer practical value by significantly reducing treatment times, easing staffing pressures, and enhancing efficiency in oncology practices, ultimately supporting a more scalable and sustainable care model.
Watch
